Vaccine · 2025
From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lindsey Kathleen M, Farrell Zachary, Tutino Rebecca, Kowalski-Dobson Theresa, Chu Zijin, Gherasim Carmen, Cai Shuwei, Simjanovski Gabriel, Manthei David, Stoneman Emily, Krammer Florian, Valdez Riccardo, Gordon Aubree
Аннотация
OBJECTIVES: Determining infection histories of individuals with prior immunity is critical to studying SARS-CoV-2 imprinting and vaccine responses. To better understand the response to infection, we examine nucleocapsid protein antibody dynamics around first and second SARS-CoV-2 infections in vaccinated and unvaccinated adults.
METHODS: The presence and levels of nucleocapsid-antibodies were measured around first and second SARS-CoV-2 infections. Antibody waning was measured with accelerated failure time models.
RESULTS: After first-infections 95.8 % (88.5-98.6 %) of unvaccinated and 89.4 % (86.5-91.7 %) of vaccinated participants seroconverted. Vaccinated adults had 45.5 % shorter seropositivity (event time ratio = 0.55, 95 %CI: 0.45-0.66). After second-infections, 89.1 % (76.9-95.3 %) of vaccinated and 94.4 % (74.2-99.0 %) of unvaccinated participants had a 4-fold rise in antibody levels. Regardless of vaccination, antibody levels after second-infections are significantly higher than after first-infections.
CONCLUSIONS: These findings suggest nucleocapsid serology can inform researchers about past infections regardless of exposure status, and potentially differentiate between initial infections and reinfections.
METHODS: The presence and levels of nucleocapsid-antibodies were measured around first and second SARS-CoV-2 infections. Antibody waning was measured with accelerated failure time models.
RESULTS: After first-infections 95.8 % (88.5-98.6 %) of unvaccinated and 89.4 % (86.5-91.7 %) of vaccinated participants seroconverted. Vaccinated adults had 45.5 % shorter seropositivity (event time ratio = 0.55, 95 %CI: 0.45-0.66). After second-infections, 89.1 % (76.9-95.3 %) of vaccinated and 94.4 % (74.2-99.0 %) of unvaccinated participants had a 4-fold rise in antibody levels. Regardless of vaccination, antibody levels after second-infections are significantly higher than after first-infections.
CONCLUSIONS: These findings suggest nucleocapsid serology can inform researchers about past infections regardless of exposure status, and potentially differentiate between initial infections and reinfections.